Explanipedia

Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment-free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co-primary endpoint Open

Elisabetta Abruzzese, Renato Bassan, Massimiliano Bonifacio, Isabella Capodanno, Francesco Cavazzini , et al. · 2025

Treatment-free remission is one of the most important goals of CML treatment but so far, the best treatment to reach this aim is still undefined, even though it is widely accepted that a sustained DMR is the prerequisite to discontinue TKI…

Clinical Impact of Graft Cryopreservation on Allogeneic Stem Cell Transplantation: An Italian, Registry‐Based Study on Behalf of the “Gruppo Italiano Per Il Trapianto di Midollo Osseo, Cellule Staminali Emopoietiche e Terapia Cellulare” (GITMO) Open

Irene Defrancesco, Virginia Valeria Ferretti, Patrizia Chiusolo, Domenico Russo, Chiara Nozzoli , et al. · 2025

The coronavirus disease 2019 (COVID‐19) pandemic created major challenges for allogeneic hematopoietic stem cell transplantation (allo‐HSCT). Scientific societies and authorities recommended cryopreserving grafts before starting conditioni…

51 | LONG‐TERM BENEFIT AND MOLECULAR FEATURES OF PATIENTS WITH HCV‐ASSOCIATED INDOLENT LYMPHOMAS TREATED WITH DIRECT‐ACTING ANTIVIRALS: 6‐YEAR FOLLOW‐UP OF THE FIL_BArT STUDY Open

Michele Merli, Elisa Genuardi, Silvia Zibellini, Sara Rattotti, Michele Spina , et al. · 2025

INO‐CD22: A multicenter, real‐world study of inotuzumab ozogamicin safety and effectiveness in adult patients with relapsed/refractory acute lymphoblastic leukemia Open

Cristina Papayannidis, Elisabetta Petracci, Patrizia Zappasodi, Nicola Fracchiolla, Fabio Ciceri , et al. · 2025

Background Inotuzumab ozogamicin (IO) has helped to change the treatment paradigm in B‐cell acute lymphoblastic leukemia (B‐ALL) but real‐world data are limited. Methods The INO‐CD22 study is a multicenter retrospective cohort study of adu…

Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real‐world setting: Interim results of the Italian observational study (ROMEI) Open

Massimo Breccia, Francesca Palandri, Maurizio Martelli, Francesco Mendicino, Alessandra Malato , et al. · 2025

The study investigated ruxolitinib dosing patterns and correlations with clinical outcomes in patients with myelofibrosis from the ROMEI study. Timely and optimal ruxolitinib treatment demonstrated maximum patient benefits such as spleen s…

Large clones of clonal hematopoiesis affect outcome in mantle cell lymphoma: results from the FIL MCL0208 clinical trial Open

S Ragaini, Anna Gallì, Elisa Genuardi, Martina Gandossini, Beatrice Alessandria , et al. · 2025

Although recent evidence suggests that myeloid clonal hematopoiesis (M-CH) may influence lymphoma clinical outcome, its impact in mantle cell lymphoma (MCL) remains unclear. Here, we report a comprehensive next-generation sequencing–based …

Recent Advances in the Molecular Biology of Chronic Lymphocytic Leukemia: How to Define Prognosis and Guide Treatment Open

Annalisa Arcari, Lucia Morello, Elena Borotti, E Ronda, Rossi Angela , et al. · 2024

Chronic Lymphocytic Leukemia (CLL) is the most frequent type of leukemia in Western countries. In recent years, there have been important advances in the knowledge of molecular alterations that underlie the disease’s pathogenesis. Very het…

Patients' preferences for chronic lymphocytic leukemia treatment: The CHOICE study Open

Paolo Sportoletti, Luca Laurenti, Annalisa Chiarenza, Gianluca Gaïdano, Elisabetta Albi , et al. · 2023

Chronic lymphocytic leukemia (CLL) therapies differ in efficacy, side effects, route, frequency, and duration of administration. We assessed patient preferences for treatment attributes and evaluated associations with disease stage, treatm…

Health-related Quality of Life Profile of Newly Diagnosed Patients With Myelodysplastic Syndromes by Age, Sex, and Risk Group: A Real-world Study by the GIMEMA Open

Fabio Efficace, Wael Al Essa, Uwe Platzbecker, Pasquale Niscola, Giuseppe A. Palumbo , et al. · 2023

Health-related quality of life (HRQoL) is an important goal of therapy for patients with myelodysplastic syndromes (MDS); however, little is known about HRQoL of these patients at clinical presentation. We report HRQoL profile of newly dia…

P1686: LONG-TERM COMORBIDITY AND HEALTH PROBLEMS IN ACUTE MYELOID LEUKEMIA (AML) SURVIVORS: AN INTERNATIONAL AML SURVIVORSHIP STUDY Open

Fabio Efficace, Laura Cannella, Xavier Thomas, Meltem Kurt Yüksel, Silvia Maria Trisolini , et al. · 2023

Topic: 35. Quality of life and palliative care Background: Owing to advances made in the treatment of acute myeloid leukemia (AML), for example with regard to transplantation strategies, the number of AML survivors has increased over the l…

P1539: INFECTION-RELATED MORTALITY CLINICAL-BIOLOGICAL SCORING SYSTEM (IRM-SCORE) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: A VALIDATION STUDY IN GITMO CENTRES Open

Daniela Clerici, Carmine Liberatore, Paola M. V. Rancoita, Chiara Maria Dellacasa, Francesca Patriarca , et al. · 2023

Topic: 30. Infections in hematology (incl. supportive care/therapy) Background: Infection-related mortality (IRM) remains a major issue in the context of allogeneic hematopoietic stem cell transplantation (allo-HSCT). Recent improvement in…

P547: UPFRONT INTENSIVE TREATMENT ANALYSIS OF THE ITALIAN COHORT STUDY ON FLT3-MUTATED AML PATIENTS (FLAM): THE IMPACT OF A FLT3 INHIBITOR ADDITION TO STANDARD CHEMOTHERAPY IN THE REAL-LIFE SETTING Open

Jacopo Nanni, Antonino Mulè, Ernesta Audisio, Maria Paola Martelli, Barbara Scappini , et al. · 2023

Background: Midostaurin in combination with standard chemotherapy represents the standard of care for the treatment of newly-diagnosed (ND) FLT3-mutated Acute Myeloid Leukemia (AML) patients. However, data on the effectiveness of upfront F…

New treatment options in elderly patients with Diffuse Large B-cell Lymphoma Open

Annalisa Arcari, Federica Cavallo, Benedetta Puccini, Daniele Vallisa · 2023

Most patients with Diffuse Large B-cell Lymphoma (DLBCL) are old (>65 years of age) and this population is expected to increase in the following years. A simplified geriatric assessment based on a careful evaluation of the fitness statu…

A Fondazione Italiana Linfomi cohort study of R-COMP vs R-CHOP in older patients with diffuse large B-cell lymphoma Open

Annalisa Arcari, Luigi Rigacci, Alessandra Tucci, Benedetta Puccini, Sara Veronica Usai , et al. · 2023

Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is the most commonly used regimen for the upfront treatment of diffuse large B-cell lymphoma (DLBCL). However, it is associated with cardiotoxicity, especially …

THE IELSG39 TRIAL: EFFICACY OF FIRST‐LINE CHLAMYDIA PSITTACI ERADICATION WITH A SIX‐MONTH REGIMEN OF DOXYCYCLINE IN PATIENTS WITH STAGE‐I MALT LYMPHOMA OF THE OCULAR ADNEXAE Open

Andrés J.M. Ferreri, Marianna C. Sassone, Maria Giulia Cangi, Gilda Magliacane, Stefania Zanussi , et al. · 2023

Introduction: In geographical areas where ocular adnexal MALT lymphoma (OAML) is frequently associated with Chlamydia psittaci (Cp) infection, monotherapy with a 3-week regimen of doxycycline has been associated with an overall response ra…

Data from Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts Open

Paul M. Barr, Alessandra Tedeschi, William G. Wierda, John N. Allan, Paolo Ghia , et al. · 2023

Purpose:The phase II CAPTIVATE study investigated first-line treatment with ibrutinib plus venetoclax for chronic lymphocytic leukemia in two cohorts: minimal residual disease (MRD)-guided randomized treatment discontinuation (MRD cohort) …

Supplementary Data from Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts Open

Paul M. Barr, Alessandra Tedeschi, William G. Wierda, John N. Allan, Paolo Ghia , et al. · 2023

Supplementary Data from Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts

Supplementary Data from Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts Open

Paul M. Barr, Alessandra Tedeschi, William G. Wierda, John N. Allan, Paolo Ghia , et al. · 2023

Supplementary Data from Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts

Data from Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts Open

Paul M. Barr, Alessandra Tedeschi, William G. Wierda, John N. Allan, Paolo Ghia , et al. · 2023

Purpose:The phase II CAPTIVATE study investigated first-line treatment with ibrutinib plus venetoclax for chronic lymphocytic leukemia in two cohorts: minimal residual disease (MRD)-guided randomized treatment discontinuation (MRD cohort) …

Additional Table I from Minimal Residual Disease after Conventional Treatment Significantly Impacts on Progression-Free Survival of Patients with Follicular Lymphoma: The FIL FOLL05 Trial Open